A three way battle beckons in GM1 gangliosidosis
Early data could give clues about whether gene therapies from Sio, Passage Bio or Lysogene will come out on top in this rare inherited disease.
GW succumbs to a Jazz overture
A focus on rare diseases and regulatory acceptance of cannabis make GW the subject of a $7.2bn buyout.
Go or no go? Oncology decisions ahead for the FDA
The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.
Biohaven pops the Alzheimer’s bubble
Troriluzole has failed in an Alzheimer’s trial, reminding the markets that this is par for the course in this disease.
Lilly boosts biopharma with an early Alzheimer’s signal
Donanemab’s apparent success in a mid-stage trial can be read as support for the beta-amyloid hypothesis, but the reality is more complex.
